Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Chromatography
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register

Allena Ji on the challenges of targeted biomarker quantitation by LC–MS

26 Jun 2018
Biomarkers Interviews MS (LC–MS/MS, HRMS, IMS)

In this interview, Allena Ji (Sanofi Genzyme; MA, USA) discusses the advantages and challenges of using triple quadrupole mass spectrometry, the challenges associated with increasing biomarker assay sensitivity and how the field may be regulated and standardized.

LB_Q3-spotlight-view

Related articles:

  • Opportunities and challenges for hybrid immunoaffinity LC–MS approach for quantitative analysis of protein biomarkers
  • Validated UHPLC–MS/MS method for quantification of doxycycline in abdominal aortic aneurysm patients
  • 2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3 – LBA: immunogenicity, biomarkers and PK assays)

If you liked this interview, you might also like:

Ragu Ramanathan interviewNovel ADME biomarkers and HRMS move new medicines to patients faster
Pegah Jalili interviewPegah Jalili’s insight into biomarker discovery
LC–MS for biotherapeutics research: an interview with Timothy Olah

Related tags

biomarker Sanofi Triple quadrupole
Previous article Next article

Related articles

8 JUL 2024 INTERVIEWS

Biomarker and immunogenicity testing: an interview with Jayaprakash Kotha

The capabilities of KCAS Bio: PK, biomarkers and immunogenicity testing all under one roof
21 MAY 2025 INTERVIEWS

The capabilities of KCAS Bio: PK, biomarkers and immunogenicity testing all under one roof

6 JUN 2017 INTERVIEWS

Pegah Jalili’s insight into biomarker discovery (MilliporeSigma)

  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
Contact
Contact Us
Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2025 Bioanalysis Zone